Gyrolab is a versatile, automated analytical platform that dramatically reduces the time required to optimize and execute immunoassays. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. Applications span the entire spectrum for immunoassays and Gyrolab is now firmly established as the preferred solution for pharmacokinetic (PK) assays in the development of therapeutic proteins.
Per Carendi, CEO of SLS Invest, said, "We are very happy to have this opportunity to invest in Gyros. Erik and his management team have mapped out an exciting future for Gyros based on the real benefits that the Company's systems can deliver to developers of novel biotherapeutics. Given that biotherapeutics products are expected to play a significant role in the growth of the pharmaceutical industry as they are used in the treatment of an ever-increasing range of diseases, we are confident of Gyros' future success."
Notes to Editors:
About Gyros AB
Gyros is the world leader in automated micro-immunoassays for therapeutic protein development.
Gyrolab(R), the company's automated and open platform, is a versatile
analytical tool that dramatically reduces the time required to optimize and
execute immunoassays. Time for assay optimization is often cut from weeks to
a matter of days. This results in increased efficiency in process development
and in clinical evaluation of therapeutic proteins. T
|SOURCE Gyros AB|
Copyright©2009 PR Newswire.
All rights reserved